Russian Federation
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 143 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 17 (17–18) 12 (12–13)
Mortality (HIV+TB only) 1.4 (1–1.9) 0.98 (0.7–1.3)
Prevalence  (includes HIV+TB) 160 (74–290) 114 (51–201)
Incidence  (includes HIV+TB) 130 (120–140) 89 (82–100)
Incidence (HIV+TB only) 7.9 (6.9–9.1) 5.5 (4.8–6.4)
Case detection, all forms (%) 83 (74–91)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 19 (14–25) 49 (40–59)
MDR-TB cases among notified pulmonary
TB cases
16 000 (11 000–20 000) 25 000 (20 000–30 000)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 37 779   7 866
Pulmonary, clinically diagnosed 43 859   7 194
Extrapulmonary 8 789   566
       
Total new and relapse 106 053    
Previously treated, excluding relapses 36 480    
Total cases notified 142 533    
Among 90 427 new cases:
3 298 (4%) cases aged under 15 years; male:female ratio: 2.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 31 677 (84%) 12 066 (23%) 43 743
Laboratory-confirmed RR-/MDR-TB cases     13 521
Patients started on MDR-TB treatment     20 372
TB/HIV 2013 Number (%)
TB patients with known HIV status 69 724  
HIV-positive TB patients 4 990  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 69
Previously treated cases, excluding relapse, registered in 2012 37
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 37
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 3.7
Culture (per 5 million population) 11.6
Drug susceptibility testing (per 5 million population) 7.6
Sites performing Xpert MTB/RIF 72
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 1 827
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-26 Data: www.who.int/tb/data